Novel compounds, '1,3-selenazine derivatives' as specific inhibitors of eukaryotic elongation factor-2 kinase

Biochimica et Biophysica Acta - General Subjects

Volumn 1475, Issue 3, 2000, Pages 207-215

  Cho, Sung Ig ^a   Koketsu, Mamoru ^b   Ishihara, Hideharu ^b   Matsushita, Masayuki ^c   Nairn, Angus C ^d   Fukazawa, Hidesuke ^a   Uehara, Yoshimasa ^a  

^a NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

^b GIFU UNIVERSITY   (Japan)

^c OKAYAMA UNIVERSITY MEDICAL SCHOOL   (Japan)

^d ROCKEFELLER UNIVERSITY   (United States)

Author keywords

1,3 Selenazine derivative; Calmodulin dependent kinase III; Eukaryotic elongation factor 2 kinase; Rottlerin; Specific eukaryotic elongation factor 2 kinase inhibitor

Indexed keywords

5,6 DIHYDRO 4H 1,3 SELENAZINE DERIVATIVE; CALCINEURIN; CYCLIC AMP DEPENDENT PROTEIN KINASE; INITIATION FACTOR 2; PROTEIN KINASE C; ROTTLERIN; UNCLASSIFIED DRUG;

ARTICLE; ATHEROSCLEROSIS; CARCINOGENESIS; CELL STRAIN 3T3; CONTROLLED STUDY; ENZYME ACTIVE SITE; ENZYME INHIBITION; ENZYME KINETICS; ENZYME PURIFICATION; NONHUMAN; PRIORITY JOURNAL; PSORIASIS; SIGNAL TRANSDUCTION;

3T3 CELLS; ACETOPHENONES; ANIMALS; BENZOPYRANS; CA(2+)-CALMODULIN DEPENDENT PROTEIN KINASE; CLONING, MOLECULAR; ENZYME INHIBITORS; MICE; MOLECULAR STRUCTURE; ORGANOSELENIUM COMPOUNDS;

EID: 0034718214     PISSN: 03044165     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-4165(00)00061-1     Document Type: Article

References (56)

1. Bolen J.B., Brugge J.S. Leukocyte protein tyrosine kinases: potential targets for drug discovery. Annu. Rev. Immunol. 15:1997;371-404.
2. Anderson P. Kinase cascades regulating entry into apoptosis. Microbiol. Mol. Biol. Rev. 61:1997;33-46.
3. Pawson T., Scott J.D. Signaling through scaffold, anchoring, and adaptor proteins. Science. 278:1997;2075-2080.
4. Kolibaba K.S., Druker B. Protein tyrosine kinases and cancer. Biochim. Biophys. Acta. 1333:1997;F217-F248.
5. Levitzki A. Signal-transduction therapy: a novel approach to disease management. Eur. J. Biochem. 226:(1):1994;1-13.
6. Gescher A. Modulators of signal transduction as cancer chemotherapeutic agents - novel mechanisms and toxicities. Toxicol. Lett. 82/83:1995;159-165.
7. Fukazawa H., Li P.-M., Mizuno S., Uehara Y. Method for simultaneous detection of protein kinase A, protein kinase C, tyrosine kinase and calmodulin-dependent protein kinase activities. Anal. Biochem. 212:1993;106-110.
8. Li P.-M., Fukazawa H., Mizuno S., Uehara Y. Evaluation of protein kinase inhibitors in an assay system containing multiple kinase activities. Anticancer Res. 13:1993;1957-1964.
9. Shikano M., Onimura K., Fukai Y., Hori M., Fukazawa H., Mizuno S., Yazawa K., Uehara Y. 1a-docosahexaenoylmitomycin C: a novel inhibitor of protein tyrosine kinase. Biochem. Biophys. Res. Commun. 248:1998;858-863.
10. Kajiura T., Furumai T., Igarashi Y., Hori H., Higashi K., Ishiyama T., Uramoto M., Uehara Y., Oki T. Signal transduction inhibitors, hibarimicins A, B, C, D and G produced by Microbispora. I. Taxonomy, fermentation, isolation and physico-chemical and biological properties. J. Antiobiot. 51:1998;394-401.
11. Ishihara H., Yoshimi M., Hara N., Kato S. A facile synthesis of β-selenolactams. Angew. Chem. Int. Ed. Engl. 29:1990;530-531.
12. Ishihara H., Yoshimi M., Hara N., Ando H., Kato S. A facile preparation of O-alkyl selenocarboxylates and selenoamides via Se-alkynyl selenocarboxylates. Bull. Chem. Soc. Jpn. 63:1990;835-841.
13. Kato S., Komuro T., Kanda T., Ishihara H., Murai T. Selenothiol esters: isolation and characterization. J. Am. Chem. Soc. 115:1993;3000-3001.
14. Kawahara Y., Kato S., Kanda T., Murai T., Ishihara H. A facile preparation of rubidium and cesium selenocarboxylates. J. Chem. Soc. Chem. Commun. 3:1993;277-278.
15. 4 and Zn, Chem. Lett. (1998) 645-646.
16. Koketsu M., Suzuki N., Ishihara H. Preparation of isoselenocyanate and synthesis of carbodiimide by oxidation of selenourea. J. Org. Chem. 64:1999;6473-6475.
17. H. Ishihara, K. Yoshimura, M. Koketsu, A facile preparation of aliphatic and aromatic primary selenoamides using 4-methylseleno-benzoate as a new selenating reagent, Chem. Lett. (1998) 1287-1288.
18. 2O-assisted reaction of primary selenoamides with α, β-unsaturated ketones. J. Chem. Soc. Perkin. Trans. 1:1999;453-456.
19. Nairn A.C., Palfrey H.C. Identification of the major Mr. 100,000 substrate for calmodulin-dependent protein kinase III in mammalian cells as elongation factor 2. J. Biol. Chem. 262:1987;17299-17303.
20. Redpath N.T., Price N.T., Severinov K.V., Proud C.G. Regulation of elongation factor-2 by multisite phosphorylation. Eur. J. Biochem. 213:1993;689-699.
21. Ryazanov A.G., Shestakova E.A., Natapov P.G. Phosphorylation of elongation factor 2 by EF-2 kinase affects rate of translation. Nature. 334:1988;170-173.
22. 2+ transients. J. Biol. Chem. 262:1987;9785-9792.
23. Mackie K.P., Nairn A.C., Hampel G., Lam G., Jaffe E.A. Thrombin and histamine stimulate the phosphorylation of elongation factor 2 in endothelial cells. J. Biol. Chem. 264:1989;1748-1753.
24. 2+-mediated secretion from rat parotid acini. Biochem. J. 282:1992;877-882.
25. Redpath N.T., Foulstone E.J., Proud C.G. Regulation of translation elongation factor-2 by insulin via a rapamycin-sensitive signalling pathway. EMBO J. 15:1996;2291-2297.
26. Marin P., Nastiuk K.L., Daniel N., Girault J.A., Czernik A.J., Glowinski J., Nairn A.C., Prémont J. Glutamate-dependent phosphorylation of elongation factor-2 and inhibition of protein synthesis in neurons. J. Neurosci. 17:1997;3445-3454.
27. Bagaglio D.M., Cheng E.H., Gorelick F.S., Mitsui K., Nairn A.C., Hait W.N. Phosphorylation of elongation factor 2 in normal and malignant rat glial cells. Cancer Res. 53:1993;2260-2264.
28. Parmer T.G., Ward M.D., Yurkow E.J., Vyas V.H., Kearney T.J., Hait W.N. Activity and regulation by growth factors of calmodulin-dependent protein kinase III (elongation factor-2 kinase) in human breast cancer. Br. J. Cancer. 79:1999;59-64.
29. Nilsson A., Nygard O. Phosphorylation of eukaryotic elongation factor 2 in differentiating and proliferating HL-60 cells. Biochim. Biophys. Acta. 1268:1995;263-268.
30. Celis J.E., Madsen P., Ryazanov A.G. Increased phosphorylation of elongation factor 2 during mitosis in transformed human amnion cells correlates with a decreased rate of protein synthesis. Proc. Natl. Acad. Sci. USA. 87:1990;4231-4235.
31. Brady M.J., Nairn A.C., Wagner J.A., Palfrey H.C. Nerve growth factor-induced downregulation of calmodulin-dependent kinase III in PC12 cells involves cyclic AMP-dependent protein kinase. J. Neurochem. 54:1990;1034-1039.
32. Severinov K.V., Melnikova E.G., Ryazanov A.G. Downregulation of the translation elongation factor 2 kinase in Xenopus laevis oocytes at the final stages of oogenesis. New Biol. 2:1990;887-893.
33. Hunter T. Protein kinase classification. Methods Enzymol. 200:1991;3-37.
34. Taylor S.S., Bubis J., Toner-Webb J., Saraswat L.D., First E.A., Buechler J.A., Knighton D.R., Sowadski J. cAMP-dependent protein kinase: prototype for a family of enzymes. FASEB J. 2:1988;2677-2685.
35. Redpath N.T., Price N.T., Proud C.G. Cloning and expression of cDNA encoding protein synthesis elongation factor-2 kinase. J. Biol. Chem. 271:1996;17547-17554.
36. Ryazanov A.G., Ward M.D., Mendola C.E., Pavur K.S., Dorovkov M.V., Wiedmann H., Erdjument-Bromage H., Tempst P., Parmer T.G., Prostko C.R., Germino F.J., Hait W.N. Identification of a new class of protein kinases represented by eukaryotic elongation factor-2 kinase. Proc. Natl. Acad. Sci. USA. 94:1997;4884-4889.
37. Côté G.P., Luo X., Murphy M.B., Egelhoff T.T. Mapping of the novel protein kinase catalytic domain of Dictyostelium myosin II heavy chain kinase A. J. Biol. Chem. 272:1997;6846-6849.
38. Ryazanov A.G., Pavur K.S., Dorovkov M.V. Alpha-kinases: a new class of protein kinases with a novel catalytic domain. Curr. Biol. 9:1999;R43-45.
39. Gschwendt M., Muller H.-J., Kielbassa K., Zang R., Kittstein W., Rincke G., Marks F. Rottlerin, a potent kinase inhibitor. Biochem. Biophys. Res. Commun. 199:1994;93-98.
40. Gschwendt M., Kittstein W., Marks F. Elongation factor-2 kinase: effective inhibition by the novel protein kinase inhibitor rottlerin and relative intensity towards staurosporine. FEBS Lett. 338:1994;85-88.
41. Hoff S., Blok A.P. Synthesis of substituted 6H-1,3-thiazines. Rec. Trav. Chim. 92:1973;631-640.
42. V.I. Cohen, Synthesis of 2,4-distributed 1,3-selenazoles, Synthesis (1979) 66-67.
43. 2+/calmodulin-dependent protein kinase kinase. J. Biol. Chem. 273:1998;21473-21481.
44. 2+/calmodulin-dependent protein kinase I from bovine brain. J. Biol. Chem. 262:1987;7273-7281.
45. Takeuchi-Suzuki E., Tanaka T., Hink W.F., King M.M. High-level expression using baculovirus, purification, and characterization of a monomeric form of Type II calmodulin-dependent protein kinase. Protein Expr. Purif. 3:1992;160-164.
46. Kemp B.E., Bylund D.B., Huang T.-S., Krebs E.G. Substrate specificity of the cyclic AMP-dependent protein kinase. Proc. Natl. Acad. Sci. USA. 72:1975;3448-3452.
47. Flockhart D.A., Corbin J.D. Regulatory mechanisms in the control of protein kinases. CRC Crit. Rev. Biochem. 12:1982;133-186.
48. Yasuda I., Kishimoto A., Tanaka S.-I., Tominaga M., Sakurai A., Nishizuka Y. Synthetic peptide substrate for selective assay of protein kinase C. Biochem. Biophys. Res. Commun. 166:1990;1220-1227.
49. Carpenter G., King L.J., Cohen S. Epidermal growth factor stimulates phosphorylation in membrane preparations in vitro. Nature. 276:1978;409-410.
50. Uehara Y., Fukazawa H., Murakami Y., Mizuno S. Irreversible inhibition of v-src tyrosine kinase activity by herbimycin A and its abrogation by sulfhydryl compounds. Biochem. Biophys. Res. Commun. 163:1989;803-809.
51. A.R. Katritzky, C.W. Rees, E.F.V. Scriven, Comprehensive Heterocyclic Chemistry II. A Review of the Literature 1982-1995, Vols. 1-11, Pergamon, 1996, Oxford.
52. Murai T., Kakami K., Hayashi K., Komura T., Takada H., Fujii M., Kanda T., Kato S. Selenothioic acid S-esters: synthesis, characterization, and trend for stability. J. Am. Chem. Soc. 119:1997;8592-8597.
53. Parmer T.G., Ward M.D., Hait W.N. Effects of rottlerin, an inhibitor of calmodulin-dependent kinase III, on cellular proliferation, viability, and cell cycle distribution in malignant glioma cells. Cell Growth Differ. 8:1997;327-334.
54. 14C]herbimycin A and its use in the elucidation of the kinase inactivation mechanism. FEBS Lett. 340:1994;155-158.
55. Diggle T.A., Charnjit C.K., Hase S., Redpath N.T. Analysis of the domain structure of elongation factor-2 kinase by mutagenesis. FEBS Lett. 457:1999;189-192.
56. Maru Y., Owen N.W. The BCR gene encodes a novel serine/threonine kinase activity within a single exon. Cell. 67:1991;459-468.